Trial Profile

A pivotal Phase 3 trial of VAX-31

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 23 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VAX 31 (Primary)
Indications Pneumococcal infections
Focus Registrational; Therapeutic Use

Most Recent Events

03 Sep 2024 According to a Vaxcyte media release, following an FDA End-of-Phase 2 meeting, the company will initiate Phase 3 pivotal, non-inferiority study by mid-2025 and announce topline safety, tolerability and immunogenicity data in 2026.
04 Mar 2024 New trial record
27 Feb 2024 According to a Vaxcyte media release, the company plans to initiate phase 3 studies in 2025 and 2026 following data from Vax-31 1/2 study in third quarter.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com